載入中
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
前收盤價
US$67.94
+US$0.07 · +0.10%
盤中時間採用ET。市場資料可能有所延遲。
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
日內區間
目前US$67.94
52週區間
目前US$67.94
盤中時間採用ET。市場資料可能有所延遲。
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
日內區間
目前US$67.94
52週區間
目前US$67.94
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 16.7萬 USD | — | — | — | — |
| 毛利 | −16.7萬 USD | — | — | — | — |
| 研究與開發 | 1.45億 USD | 1.04億 USD | 6059.4萬 USD | 3528.95萬 USD | 2575.8萬 USD |
| 銷售、一般及管理費用 | 2719.7萬 USD | 906.37萬 USD | 563.63萬 USD | 438.04萬 USD | 259.79萬 USD |
| 營業費用 | 1.72億 USD | 1.13億 USD | 6623.03萬 USD | 3939.11萬 USD | 2835.59萬 USD |
| 利息收入 | 1229.8萬 USD | 1176.83萬 USD | 777.76萬 USD | 112.72萬 USD | 1.33萬 USD |
| 利息支出 | 1714.8萬 USD | 1028.04萬 USD | 532.64萬 USD | 210.61萬 USD | 126.24萬 USD |
| 折舊和攤銷 | 16.7萬 USD | 12.99萬 USD | 14.28萬 USD | 21.09萬 USD | 30.32萬 USD |
| 營業利益 | −1.72億 USD | −1.13億 USD | −6623.03萬 USD | −3939.11萬 USD | −2835.59萬 USD |
| 淨利 | −1.77億 USD | −1.12億 USD | −6377.91萬 USD | −4037萬 USD | −2960.53萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$159.88
上漲空間 135.33%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.24億0.01%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI8234.3萬0.83%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM6873.31萬0.09%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF3938.09萬0.04%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO2410.91萬0.17%139.17億 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO1969.8萬0.11%180億 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA1476.24萬0.07%218.24億 USD0.03%US$32.79+0.40%
Vanguard Health Care ETFVHT696.21萬0.03%220億 USD0.09%US$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
